Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
Jason B. Gibbons, PhD
Advertisement
Articles by Jason B. Gibbons, PhD
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Medicare beneficiaries attributed to small practices in accountable care organizations (ACOs) achieve greater savings than beneficiaries attributed to large practices in ACOs.
Advertisement
Latest Updated Articles
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender AdultsPublished: August 18th 2025 | Updated: August 25th 2025
Semaglutide Not Associated With Increased Risk of Eye DisordersPublished: August 19th 2025 | Updated: August 22nd 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?Published: June 6th 2025 | Updated: August 18th 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health SystemPublished: June 27th 2025 | Updated: July 1st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPPPublished: February 20th 2025 | Updated: February 21st 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC CasesPublished: January 16th 2025 | Updated: January 29th 2025
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Metabolic Issues More Common in Patients With HIV
3
Iron Dysregulation Linked to MS Progression, Review Finds
4
Efficacy of Ruxolitinib Cream in Nonsegmental Vitiligo Confirmed in Real-World Study
5
